nivolumab plus ipilimumab (n=14) vs. nivolumab alone (n=13)
randomized controlled trial
nivolumab plus ipilimumab
480 mg of nivolumab IV every 4 weeks plus 1 mg/kg of ipilimumab IV every 6 weeks up to 4 doses before and after surgery
nivolumab
240 mg of nivolumab intravenously (IV) every 2 weeks alone
mHCC - (neo)adjuvant (NA)
Patient can have had prior treatment for HCC including prior surgery, radiation therapy, local-regional therapy (ablation or arterial directed therapies), and systemic therapy including sorafenib or chemotherapy
open design
single-center
The goal of this arm was to study if unresectable localized disease will have adequate tumor shrinkage to become resectable.
CheckMate 9DW, 2024 NCT04039607
nivolumab plus ipilimumab plus SoC (n=-9) vs. VEGF(R) inhibitor (n=-9)
randomized controlled trial
nivolumab and ipilimumab
Opdivo 1mg/kg plus Yervoy 3 mg/kg Q3W for up to four doses, followed by Opdivo monotherapy 480 mg Q4W